Redx Pharma

20 articles with Redx Pharma

• 

  Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx

  2/23/2023

  One day after revealing a restructuring initiative, Jounce Therapeutics announced it plans to merge its business in an all-stock deal with clinical-stage biotech Redx Pharma. 

• Redx and Jounce Announce Recommended Business Combination

  2/23/2023

  Redx Pharma and Jounce Therapeutics, Inc. announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction.

• 

  Jazz and Redx Tout IND Acceptance while Omega Seeks First

  6/15/2022

  Jazz Pharmaceuticals, Redx Pharma and Omega Therapeutics are pushing forward with their cancer treatments with Investigational New Drug approval and IND application submission.

• Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types

  4/8/2022

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and collaboration partner Redx Pharma (AIM: REDX) today presented data showing the pan-RAF kinase inhibitor, JZP815, was active in multiple RAF- and RAS-mutant tumor pre-clinical models, with a pharmacokinetic profile that may provide drug exposure required for target engagement in humans.

• Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies

  9/9/2020

  Research Collaboration on Two Targeted Oncology Programs in the Ras/Raf/MAP Kinase Pathway Redx to Receive $10 Million Upfront and $10 Million in Year 2 with up to $400 Million in Further Milestone Payments Plus Tiered Royalties on any Future Net Product Sales

• Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma

  7/10/2019

  Pan-RAF Program adds an Early Stage, Innovative, Precision Oncology Asset to Jazz Pharmaceuticals' Growing R&D Portfolio

• 

  RedX Pharma Cancer Trial Paused: Serious Side Effects

  3/29/2018

  Redx Pharma dosed its first patient for the Porcupine inhibitor RXC004 on February 6. The company indicates it has paused the trial after the first patient dosed had “clinically significant” adverse events.

• Redx Pharma Cuts 86 Jobs As Group Shifts Focus

  3/24/2017

• Redx Pharma To Present Pre-Clinical Profile Of Its Reversible BTK Inhibitor At American Society of Hematology 2016

  11/4/2016

• Redx Pharma CFO to Step Down Just as Former AstraZeneca PLC Exec Joins Roster

  9/8/2016

• Redx Pharma Consolidates Three Business Units and Sets Up Shop at Ex-AstraZeneca PLC Site

  4/15/2016

• Horizon Discovery Group plc And Redx Pharma Sign Cancer Research Collaboration

  9/3/2015

• Redx Pharma To Raise £15 Million On Stock Market Debut

  3/26/2015

• Tiny Redx Pharma Signs "Transformational" Cancer Deal With AstraZeneca PLC; Financial Terms Have Not Been Disclosed

  9/4/2014

• Redx Pharma To Create107 New High-Paying Jobs With Government Grant

  4/10/2014

• Redx Pharma Creates 120 New Jobs at Site Being Vacated by AstraZeneca PLC

  5/7/2013

• The Dotmatics Enterprise Platform is Licensed by Redx Pharma to Aid Their Quest to Develop New Drug Candidates

  1/30/2013

• UK's Redx Pharma to Create 100 New Jobs

  10/19/2012

• Redx Pharma to Create 119 New Jobs in Liverpool

  6/29/2012

• Cresset Group and Redx Pharma Announce Major Drug Discovery Collaboration

  8/24/2011